http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/ News About Tech, Money and Innovation Wed, 25 Nov 2009 06:07:42 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/comment-page-1/#comment-453644 VentureBeat » Double vision: Ophthotech, Eyetech and Lux BioSciences Fri, 17 Aug 2007 02:44:03 +0000 http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/#comment-453644 [...] originally acquired it from… Eyetech. A second deal brought in more aptamers from Archemix (see our coverage), which bought Gilead Sciences‘ aptamer technology in 2001, gaining control of everything [...] [...] originally acquired it from… Eyetech. A second deal brought in more aptamers from Archemix (see our coverage), which bought Gilead Sciences‘ aptamer technology in 2001, gaining control of everything [...]

]]> http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/comment-page-1/#comment-422760 VentureBeat » Life sciences briefing: Monday, Aug. 13, 2007 Mon, 13 Aug 2007 20:17:01 +0000 http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/#comment-422760 [...] Newly formed Ophthotech raises $36M against eye disease — Ophthotech, a newly formed Princeton, N.J., biotech with a focus on eye disease, raised a whopping $36 million in a first funding round. The company, founded by a bevy of former Eyetech Pharmaceuticals, is going to follow directly in the former company’s footsteps by taking aim at age-related macular degeneration with aptamers licensed from Archemix (which we wrote about here). [...] [...] Newly formed Ophthotech raises $36M against eye disease — Ophthotech, a newly formed Princeton, N.J., biotech with a focus on eye disease, raised a whopping $36 million in a first funding round. The company, founded by a bevy of former Eyetech Pharmaceuticals, is going to follow directly in the former company’s footsteps by taking aim at age-related macular degeneration with aptamers licensed from Archemix (which we wrote about here). [...]

]]> http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/comment-page-1/#comment-401694 VentureBeat » Biotech financing: Will ImaRx break the IPO slump? Sat, 11 Aug 2007 00:01:08 +0000 http://venturebeat.com/2007/07/25/aptamer-drug-maker-archemix-files-for-69m-ipo/#comment-401694 [...] IPO in almost two months. The slowdown hasn’t stopped companies from filing — yesterday Archemix joined the list, and the day before brought us Cumberland Pharmaceuticals setting its offering price. Still, the [...] [...] IPO in almost two months. The slowdown hasn’t stopped companies from filing — yesterday Archemix joined the list, and the day before brought us Cumberland Pharmaceuticals setting its offering price. Still, the [...]

]]>